 Amryt Pharma PLC LON:AMYT, NASDAQ:AMYT said it expects to continue strong sales growth for 2021 after reporting a first underlying profit and strong cash flow for the past year. The biopharma company, which acquires, develops and commercialises novel treatments for rare diseases, generated revenue growth of 18.5 to US182.6mln for 2020 from its two products on the market, metreleptin as a supplement for people with leptin deficiency and lomitapide, for adults with a rare cholesterol disorder. 